Imaging agent developer ImaginAb has signed a licensing agreement with the University of California, Los Angeles (UCLA) for immune cell imaging agents.
Under the technology licensing agreement, ImaginAb receives exclusive access to novel PET imaging agents that target specific markers of murine T-cells. The company said it believes this will enable a new understanding of response to immunotherapeutic drugs in preclinical models.
Imaging T-cell targets such as CD3 and CD8 could improve upon the limited efficacy of tissue- and blood-based biomarker strategies to predict and monitor response to drugs against targets such as PD-1/L1 or CTLA4 checkpoint inhibitors, ImaginAb said.
